Shiga, Japan

Shinpei Sugiyama



Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018-2019

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Shinpei Sugiyama

Introduction

Shinpei Sugiyama is a notable inventor based in Shiga, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of prodrugs for therapeutic applications. With a total of two patents to his name, Sugiyama's work focuses on enhancing the stability and efficacy of existing treatments.

Latest Patents

Sugiyama's latest patents include innovations related to silyl etherified derivatives of 5-azacytidines in carbohydrate moiety. These inventions aim to provide a prodrug of 5-azacytidine or 2'-deoxy-5-azacytidine that exhibits remarkable stability against cytidine deaminase, a metabolic hydrolyzing enzyme. This advancement is particularly relevant as it seeks to replace current injections of 5-azacytidine or 2'-deoxy-5-azacytidine, which are clinically used as therapeutic agents for various myelomas, including myelodysplastic syndrome. The compounds developed by Sugiyama are represented by specific chemical formulas, showcasing his expertise in medicinal chemistry.

Career Highlights

Sugiyama is associated with Ohara Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing drug formulations that improve patient outcomes.

Collaborations

One of his notable collaborators is Magoichi Sako, with whom he has worked on various projects aimed at enhancing drug stability and efficacy.

Conclusion

Shinpei Sugiyama's contributions to pharmaceutical innovations highlight his commitment to improving therapeutic options for patients. His patents reflect a deep understanding of medicinal chemistry and a dedication to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…